MA26948A1 - Guanidinobenzamides comme mc4-r agonistes. - Google Patents

Guanidinobenzamides comme mc4-r agonistes.

Info

Publication number
MA26948A1
MA26948A1 MA27062A MA27062A MA26948A1 MA 26948 A1 MA26948 A1 MA 26948A1 MA 27062 A MA27062 A MA 27062A MA 27062 A MA27062 A MA 27062A MA 26948 A1 MA26948 A1 MA 26948A1
Authority
MA
Morocco
Prior art keywords
guanidinobenzamides
agonists
Prior art date
Application number
MA27062A
Other languages
English (en)
Inventor
Paul A Renhowe
Daniel Chu
Rustum Boyce
Zhi-Jie Ni
David Duhl
Effie Tozzo
Kirk Johnson
David Myles
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of MA26948A1 publication Critical patent/MA26948A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA27062A 2000-08-31 2003-02-28 Guanidinobenzamides comme mc4-r agonistes. MA26948A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23056500P 2000-08-31 2000-08-31
US24557900P 2000-11-06 2000-11-06

Publications (1)

Publication Number Publication Date
MA26948A1 true MA26948A1 (fr) 2004-12-20

Family

ID=26924350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27062A MA26948A1 (fr) 2000-08-31 2003-02-28 Guanidinobenzamides comme mc4-r agonistes.

Country Status (27)

Country Link
US (2) US6638927B2 (fr)
EP (1) EP1409468B9 (fr)
JP (1) JP4166567B2 (fr)
KR (1) KR20030034163A (fr)
CN (1) CN1659156A (fr)
AP (1) AP2003002755A0 (fr)
AT (1) ATE414067T1 (fr)
AU (2) AU2001288604B2 (fr)
BG (1) BG107639A (fr)
BR (1) BR0113643A (fr)
CA (1) CA2420694C (fr)
CZ (1) CZ2003882A3 (fr)
DE (1) DE60136571D1 (fr)
DZ (1) DZ3415A1 (fr)
EA (1) EA200300323A1 (fr)
ES (1) ES2316467T3 (fr)
HU (1) HUP0302067A2 (fr)
IL (1) IL154604A0 (fr)
MA (1) MA26948A1 (fr)
MX (1) MXPA03001813A (fr)
NO (1) NO20030929L (fr)
NZ (1) NZ524897A (fr)
PL (1) PL360698A1 (fr)
PT (1) PT1409468E (fr)
SI (1) SI21267A (fr)
SK (1) SK3832003A3 (fr)
WO (1) WO2002018327A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002310409C1 (en) * 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20070004743A1 (en) * 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
AU2003245325A1 (en) * 2002-05-23 2003-12-12 Chiron Corporation Substituted quinazolinone compounds
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
ATE440827T1 (de) * 2002-12-04 2009-09-15 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
WO2004087153A2 (fr) 2003-03-28 2004-10-14 Chiron Corporation Utilisation de petites molecules de composes pour une immunopotentialisation
WO2004112793A1 (fr) * 2003-05-23 2004-12-29 Chiron Corporation Composes de quinazoline substitues par guanidino constituant des agonistes de mc4-r
JP2005306839A (ja) * 2003-08-29 2005-11-04 Takeda Chem Ind Ltd 二環性ピペラジン化合物およびその用途
EP1661898A4 (fr) 2003-08-29 2009-04-15 Takeda Pharmaceutical Compose de piperazine bicyclique et utilisation de ce dernier
CA2545601A1 (fr) 2003-11-19 2005-06-09 Chiron Corporation Composes de quinazolinone avec bioaccumulation reduite
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7795448B2 (en) 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
MX2007005306A (es) 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
EP1917244A2 (fr) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5
MX2008015454A (es) 2006-06-09 2009-01-30 Action Pharma As Derivados de fenil-pirrol-aminoguanidina.
GB0624987D0 (en) 2006-12-14 2007-01-24 Acure Pharma Ab Novel aminoguanidines as melanocortin receptor ligands
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
CA2743489A1 (fr) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Amines bicycliques substituees pour le traitement du diabete
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
WO2011137024A1 (fr) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011156246A1 (fr) 2010-06-11 2011-12-15 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de prolylcarboxypeptidase
CA2825098C (fr) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine et derives de pyrazolopyrimidine en tant que modulateurs du recepteur de la melanocortine-4
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
CN115850117B (zh) * 2022-11-15 2024-06-04 黎明化工研究设计院有限责任公司 一种制备1,4-环己烷二异氰酸酯的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177218A (en) 1962-01-17 1965-04-06 Monsanto Chemicals Methylene-bis(2-guanidino-4-methylquinazoline)
DE2623846A1 (de) 1976-05-28 1977-12-15 Hoechst Ag 4-chinazolinyl-guanidine und verfahren zu ihrer herstellung
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
DE3270716D1 (en) 1981-02-27 1986-05-28 Ici Plc Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity
EP0067508B1 (fr) 1981-05-18 1985-10-30 Imperial Chemical Industries Plc Dérivés d'amidine
US4921939A (en) * 1985-03-19 1990-05-01 Universite Claude Bernard -Lyon 1 Sweetening agents
JPS6229566A (ja) 1985-07-30 1987-02-07 Taiyo Yakuhin Kogyo Kk 新規グアニジノメチル安息香酸誘導体
US4948891A (en) 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
US4948901A (en) 1988-05-24 1990-08-14 Pfizer Inc. Benzamide protease inhibitors
US4874864A (en) 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
US5055479A (en) 1988-06-16 1991-10-08 Sankyo Company, Limited Method of treating cachexia
GB8926512D0 (en) 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
CA2032420A1 (fr) * 1989-12-22 1991-06-23 Akira Okuyama Derives de la phenylguanidine
US5124328A (en) 1990-10-11 1992-06-23 Merck & Co., Inc. Morpholine derivatives compositions and use
ATE180255T1 (de) 1993-03-23 1999-06-15 Astra Ab Guanidinderivate mit therapeutischer wirkung
AU682381B2 (en) 1993-08-12 1997-10-02 Astra Aktiebolag Amidine derivatives with nitric oxide synthetase activities
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5599984A (en) 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
US5637439A (en) 1994-11-07 1997-06-10 Mitsubishi Paper Mills Ltd. Photographic silver halide photosensitive material and method for developing the same
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE19544685A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69710319T2 (de) 1996-03-29 2002-08-14 Searle & Co Para-substituierte phenylpropansäure derivate als integrin-antagonisten
ZA973850B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US6127343A (en) 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
DK0984778T3 (da) 1996-08-23 2002-09-16 Agouron Pharma Neuropeptid-Y-ligander
WO1998018786A1 (fr) 1996-10-31 1998-05-07 Novo Nordisk A/S Agonistes et antagonistes contraints de somatostatine
CN1104422C (zh) 1996-11-25 2003-04-02 普罗克特和甘保尔公司 用作α－2肾上腺素能受体***的胍基杂环化合物
WO1997041119A1 (fr) 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Nouveaux composes anti-diabetiques avec proprietes hypolipidemiantes et anti-hypertensives, procede pour les preparer et compositions pharmaceutiques contenant ces composes
AU742425B2 (en) * 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19831710A1 (de) * 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
EP1156803A4 (fr) 1999-02-09 2004-03-17 Bristol Myers Squibb Co Inhibiteurs lactame de fxa et methode
WO2000074679A1 (fr) 1999-06-04 2000-12-14 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
BR0012984A (pt) * 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
AU2001228681A1 (en) 2000-01-28 2001-08-07 Melacure Therapeutics Ab Novel aromatic amines and amides acting on the melanocortin receptors
MXPA02007289A (es) 2000-01-28 2003-09-22 Melacure Therapeutics Ab Agonistas y antagonistas novedosos de receptores de melanocortina.
CA2403686C (fr) 2000-03-23 2010-01-26 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
AU2003245325A1 (en) 2002-05-23 2003-12-12 Chiron Corporation Substituted quinazolinone compounds

Also Published As

Publication number Publication date
HUP0302067A2 (hu) 2003-09-29
BG107639A (bg) 2003-11-28
JP4166567B2 (ja) 2008-10-15
CA2420694A1 (fr) 2002-03-07
ATE414067T1 (de) 2008-11-15
ES2316467T3 (es) 2009-04-16
IL154604A0 (en) 2003-09-17
AU8860401A (en) 2002-03-13
DE60136571D1 (de) 2008-12-24
WO2002018327A3 (fr) 2002-08-08
SK3832003A3 (en) 2003-11-04
CN1659156A (zh) 2005-08-24
AU2001288604B2 (en) 2005-02-24
EP1409468B9 (fr) 2009-07-29
NZ524897A (en) 2004-08-27
PT1409468E (pt) 2009-01-28
KR20030034163A (ko) 2003-05-01
DZ3415A1 (fr) 2002-03-07
CZ2003882A3 (cs) 2003-09-17
NO20030929L (no) 2003-04-30
EA200300323A1 (ru) 2003-08-28
CA2420694C (fr) 2009-06-23
US20020137939A1 (en) 2002-09-26
US6638927B2 (en) 2003-10-28
US6995269B2 (en) 2006-02-07
AP2003002755A0 (en) 2003-06-30
SI21267A (sl) 2004-02-29
US20030199499A1 (en) 2003-10-23
MXPA03001813A (es) 2004-11-01
EP1409468A2 (fr) 2004-04-21
JP2004508304A (ja) 2004-03-18
PL360698A1 (en) 2004-09-20
BR0113643A (pt) 2004-03-02
WO2002018327A2 (fr) 2002-03-07
NO20030929D0 (no) 2003-02-27
EP1409468B1 (fr) 2008-11-12

Similar Documents

Publication Publication Date Title
DZ3415A1 (fr) Guanidinobenzamides comme mc4-r agonistes.
NO20025115L (no) Muskarin agonister
MX242679B (es) Antranilamidas insecticidas.
NL1017075A1 (nl) Preparaat.
FI20000004A0 (fi) Flavonoidilääke...
NL1017973A1 (nl) Inrichting.
BR0013417B1 (pt) composiÇço aquosa.
BR0108365B1 (pt) refrigerador.
CH695519A5 (de) Sperrstromthyristor.
MXPA03001801A (es) Composicion acondicionadora pre-champu.
BR0101696B1 (pt) refrigerador.
ITTO20020744A1 (it) Composizione.
ITTO20020745A1 (it) Composizione.
IT1319677B1 (it) Composizione funghicida.
ES1046656Y (es) Microplanta de transferencia de residuos solidos urbanos.
ES1047522Y (es) Envase-aplicador de parafina.
ES1046474Y (es) Tijeras ambidiestras.
ES1046574Y (es) Juego de sobremesa.
ES1047836Y (es) Hidrobicicleta.
IT1316979B1 (it) Grigliatrice.
ES1049032Y (es) Bitubo.
ES1047305Y (es) Embudo anti-rebosamiento.
IT249307Y1 (it) Ciabatta.
ES1047010Y (es) Portalamparas.
ES1045851Y (es) Cubitera.